Literature DB >> 20018624

Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity.

Zofia M Prokopowicz1, Frederick Arce, Rafal Biedroń, Cheryl L-L Chiang, Marta Ciszek, David R Katz, Maria Nowakowska, Szczepan Zapotoczny, Janusz Marcinkiewicz, Benjamin M Chain.   

Abstract

The production of hypochlorous acid (HOCl) is a characteristic of granulocyte activation, a hallmark of the early phase of innate immune responses. In this study, we show that, in addition to its well-established role as a microbicide, HOCl can act as a natural adjuvant of adaptive immunity. HOCl enhances the T cell responses to the model Ag OVA, facilitating the processing and presentation of this protein via the class II MHC pathway. HOCl modification also enhances cross-presentation of the tumor Ag tyrosinase-related protein 2 via class I MHC. The adjuvant effects of HOCl are independent of TLR signaling. The enhanced presentation of HOCl-modified OVA is mediated via modification of the N-linked carbohydrate side chain rather than formation of protein aldehydes or chloramines. HOCl-modified OVA is taken up more efficiently by APCs and is degraded more efficiently by proteinases. Atomic force microscopy demonstrated that enhanced uptake is mediated via specific receptor binding, one candidate for which is the scavenger receptor lectin-like oxidized low-density lipoprotein receptor, which shows enhanced binding to chlorinated OVA. A function of HOCl is therefore to target glycoprotein Ags to scavenger receptors on the APC surface. This additional mechanism linking innate and adaptive immunity suggests novel strategies to enhance immunity to vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018624     DOI: 10.4049/jimmunol.0902606

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  Abundant Monovalent Ions as Environmental Signposts for Pathogens during Host Colonization.

Authors:  Shumin Tan
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

2.  Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.

Authors:  Cassandra E Callmann; Lisa E Cole; Caroline D Kusmierz; Ziyin Huang; Dai Horiuchi; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

3.  A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

4.  Analysis of novel meningococcal vaccine formulations.

Authors:  Susu M Zughaier
Journal:  Hum Vaccin Immunother       Date:  2017-04-10       Impact factor: 3.452

Review 5.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

6.  Synthesis of a highly HOCl-selective fluorescent probe and its use for imaging HOCl in cells and organisms.

Authors:  Xiaoqiang Chen; Kyung-Ah Lee; Xintong Ren; Jae-Chan Ryu; Gyungmi Kim; Ji-Hwan Ryu; Won-Jae Lee; Juyoung Yoon
Journal:  Nat Protoc       Date:  2016-06-09       Impact factor: 13.491

7.  Disruption of heme-peptide covalent cross-linking in mammalian peroxidases by hypochlorous acid.

Authors:  Husam M Abu-Soud; Dhiman Maitra; Faten Shaeib; Sana N Khan; Jaeman Byun; Ibrahim Abdulhamid; Zhe Yang; Ghassan M Saed; Michael P Diamond; Peter R Andreana; Subramaniam Pennathur
Journal:  J Inorg Biochem       Date:  2014-07-08       Impact factor: 4.155

8.  A BODIPY Based Fluorescent Probe for the Rapid Detection of Hypochlorite.

Authors:  Lusheng Wang; Bolin Li; Chao Jiang; Ruopei Sun; Peizhuo Hu; Suwen Chen; Wangsuo Wu
Journal:  J Fluoresc       Date:  2018-06-25       Impact factor: 2.217

9.  Personalized vaccination against ovarian cancer: what are the possibilities?

Authors:  Janos L Tanyi; Erin George
Journal:  Expert Rev Vaccines       Date:  2018-11-07       Impact factor: 5.217

10.  Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.

Authors:  Nicola Hardwick; Jonathan A Ledermann; Egla Aitkens; Benny Chain
Journal:  Cancer Immunol Immunother       Date:  2012-04-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.